Fluctuations in Parkinson's disease and personalized medicine: bridging the gap with the neuropsychiatric fluctuation scale.
Parkinson‘s disease
neuropsychiatric fluctuations
psychometric characteristics
scale
validation
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2023
2023
Historique:
received:
21
06
2023
accepted:
02
08
2023
medline:
4
9
2023
pubmed:
4
9
2023
entrez:
4
9
2023
Statut:
epublish
Résumé
Neuropsychiatric fluctuations (NpsyF) are frequent and disabling in people with Parkinson's disease (PD). In OFF-medication, NpsyF entail To evaluate the psychometric properties of the NFS in PD. PD patients with motor fluctuations and healthy controls (HC) were assessed. In PD patients, the NFS was administrated in both the ON-and OFF-medication conditions, together with the movement disorders society-unified Parkinson disease rating scale parts I-IV. Depression (Beck depression scale II), apathy (Starkstein apathy scale) and non-motor fluctuations items of the Ardouin scale of behaviour in PD (ASBPD OFF and ON items) were also assessed. NFS internal structure was evaluated with principal component analysis consistency (PCA) in both medication conditions in PD patients and before emotional induction in HC. NFS internal consistency was assessed using Cronbach's alpha coefficient. NFS convergent and divergent validity was measured through correlations with BDI-II, Starktein, and ASBPD OFF and ON non motor items. Specificity was assessed comparing NFS global score between the HC and PD populations. Sensitivity was evaluated with t-student test comparing the ON-and the OFF-medication conditions for NFS global score and for In total, 101 consecutive PD patients and 181 HC were included. In PD patients and HC, PCA highlighted one component that explained 32-35 and 42% of the variance, respectively. Internal consistency was good for both the NFS The satisfactory properties of the NFS support its use to assess acute neuropsychiatric fluctuations in PD patients, adding to available tools.
Sections du résumé
Background
UNASSIGNED
Neuropsychiatric fluctuations (NpsyF) are frequent and disabling in people with Parkinson's disease (PD). In OFF-medication, NpsyF entail
Objective
UNASSIGNED
To evaluate the psychometric properties of the NFS in PD.
Methods
UNASSIGNED
PD patients with motor fluctuations and healthy controls (HC) were assessed. In PD patients, the NFS was administrated in both the ON-and OFF-medication conditions, together with the movement disorders society-unified Parkinson disease rating scale parts I-IV. Depression (Beck depression scale II), apathy (Starkstein apathy scale) and non-motor fluctuations items of the Ardouin scale of behaviour in PD (ASBPD OFF and ON items) were also assessed. NFS internal structure was evaluated with principal component analysis consistency (PCA) in both medication conditions in PD patients and before emotional induction in HC. NFS internal consistency was assessed using Cronbach's alpha coefficient. NFS convergent and divergent validity was measured through correlations with BDI-II, Starktein, and ASBPD OFF and ON non motor items. Specificity was assessed comparing NFS global score between the HC and PD populations. Sensitivity was evaluated with t-student test comparing the ON-and the OFF-medication conditions for NFS global score and for
Results
UNASSIGNED
In total, 101 consecutive PD patients and 181 HC were included. In PD patients and HC, PCA highlighted one component that explained 32-35 and 42% of the variance, respectively. Internal consistency was good for both the NFS
Conclusion
UNASSIGNED
The satisfactory properties of the NFS support its use to assess acute neuropsychiatric fluctuations in PD patients, adding to available tools.
Identifiants
pubmed: 37662035
doi: 10.3389/fneur.2023.1242484
pmc: PMC10469620
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1242484Informations de copyright
Copyright © 2023 Schmitt, Debu, Castrioto, Kistner, Fraix, Bouvard and Moro.
Déclaration de conflit d'intérêts
EM has received honoraria from Medtronic for consulting services. She has also received research grant support from the Grenoble Alpes University, Abbott, Ipsen, and France Parkinson. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Neuropsychiatry Clin Neurosci. 1992 Spring;4(2):134-9
pubmed: 1627973
Brain. 2013 May;136(Pt 5):1568-77
pubmed: 23543483
Parkinsonism Relat Disord. 2012 May;18(4):382-5
pubmed: 22243835
Mov Disord. 2016 Aug;31(8):1103-13
pubmed: 27041545
Neurology. 1995 Sep;45(9):1757-60
pubmed: 7675241
J Pers Assess. 1996 Dec;67(3):588-97
pubmed: 8991972
Rev Neurol (Paris). 2018 Nov;174(9):653-663
pubmed: 30224159
Int Rev Neurobiol. 2017;134:947-971
pubmed: 28805590
Brain. 2012 May;135(Pt 5):1463-77
pubmed: 22508959
Arch Clin Neuropsychol. 1997;12(3):269-75
pubmed: 14588419
J Neural Transm (Vienna). 2015 Dec;122(12):1673-84
pubmed: 26264174
Front Psychol. 2016 Aug 03;7:1141
pubmed: 27536260
Mov Disord. 2005 Jun;20(6):726-33
pubmed: 15719426
Mov Disord. 2001 Mar;16(2):197-201
pubmed: 11295770
Mov Disord. 2008 Apr 30;23(6):830-6
pubmed: 18307246
Brain. 2010 Apr;133(Pt 4):1111-27
pubmed: 20237128
Brain. 1996 Dec;119 ( Pt 6):2121-32
pubmed: 9010015
Mov Disord. 2008 Nov 15;23(15):2129-70
pubmed: 19025984
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Parkinsons Dis. 2011;2011:292719
pubmed: 21860778
Mov Disord. 2016 Aug;31(8):1080-94
pubmed: 27431515
Neurology. 1993 Aug;43(8):1459-64
pubmed: 8350996
Neurol Clin Pract. 2021 Jun;11(3):e232-e238
pubmed: 34484896
Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S80-4
pubmed: 22166463
Eur J Neurol. 2004 May;11(5):315-20
pubmed: 15142224
Arch Neurol. 1988 Nov;45(11):1194-9
pubmed: 3190499
Parkinsonism Relat Disord. 2013 Jan;19(1):104-8
pubmed: 22981261
Rev Neurol (Paris). 2009 Nov;165(11):845-56
pubmed: 19683776
Parkinsonism Relat Disord. 2008;14(3):205-12
pubmed: 17900967
Mov Disord Clin Pract. 2018 Mar 23;5(3):265-272
pubmed: 30363450
Mov Disord. 1995 May;10(3):329-32
pubmed: 7651451
Neurology. 2013 Feb 26;80(9):800-9
pubmed: 23365054
Mov Disord. 2015 Apr 15;30(5):705-13
pubmed: 25809278
Neurology. 2002 Aug 13;59(3):408-13
pubmed: 12177375
Neurol Sci. 2022 Jun;43(6):3641-3647
pubmed: 35043355
Brain. 2002 Mar;125(Pt 3):584-94
pubmed: 11872615
Rev Neurol (Paris). 2022 Apr;178(4):347-354
pubmed: 34565624